Evidence map›Paper›PMID 36711425›Full record

ReviewParticle & particle systems characterization : measurement and description of particle properties and behavior in powders and other disperse systems2023

Tackling COVID-19 Using Antiviral Nanocoating's-Recent Progress and Future Challenges.

Krishanu Ghosal

Open access · greenAbstract readReview
In one paragraph

Review in Particle & particle systems characterization : measurement and description of particle properties and behavior in powders and other disperse systems, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Tackling COVID-19 Using Antiviral Nanocoating's-Recent Progress and Future Challenges.Particle & particle systems characterization : measurement and description of particle properties and behavior in powders and other disperse systems · 2023
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 2 countries.

Krishanu GhosalResearch & Development Laboratory Shalimar Paints Limited Nashik Maharashtra 422403 India.ORCID https://orcid.org/0000-0003-3399-1413
Technion – Israel Institute of Technology · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the current situation of the global coronavirus disease 2019 (COVID-19) pandemic, there is a worldwide demand for the protection of regular handling surfaces from viral transmission to restrict the spread of COVID-19 infection. To tackle this challenge, researchers and scientists are continuously working on novel antiviral nanocoatings to make various substrates capable of arresting the spread of such pathogens. These nanocoatings systems include metal/metal oxide nanoparticles, electrospun antiviral polymer nanofibers, antiviral polymer nanoparticles, graphene family nanomaterials, and etched nanostructures. The antiviral mechanism of these systems involves depletion of the spike glycoprotein that anchors to surfaces by the nanocoating and makes the spike glycoprotein and viral nucleotides inactive; however, the nature of the interaction between the spike proteins and virus depends on the type of nanostructure and a surface charge over the coating surface. In this article, the current scenario of COVID-19 and how it can be tackled using antiviral nanocoatings from the further transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), along with their different mode of action, are discussed. Additionally, it is also highlighted different types of nanocoatings developed for various substrates to encounter transmission of SARS-CoV-2, future research areas along with the current challenges related to it, and how these challenges can be resolved.

Indexed as

coronavirus disease 2019nanocoatingnanomaterialspathogenssevere acute respiratory syndrome coronavirus 2

Identifiers

PMID36711425
PMCPMC9874835
OpenAlexW4303614606

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.